SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending amid a notable price decline and reports of significant ETF outflows, sparking intense community debate as bears foresee further collapse while bulls view it as a generational buying opportunity, with many closely watching MicroStrategy's holdings.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending due to Bitcoin's sharp price decline, which has deepened the company's unrealized losses on its significant crypto holdings, fueling intense community debate over potential "liquidation" or "bankruptcy" while others see a "buy the dip" opportunity ahead of its anticipated earnings.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is a top trending crypto, experiencing significant price declines amidst a broad market sell-off and intense community debate. While some attribute the plunge to market manipulation and speculative links to "Epstein files," others view the deep dip as a prime opportunity, highlighting positive developments like a major Saudi bank partnership and XRPL network upgrades, anticipating future institutional utility and regulatory clarity.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending amid a broad tech sector sell-off, driven by concerns over aggressive AI-related capital expenditures from major companies like Google and a significant rotation out of software stocks. The community is actively debating whether current losses are overdone, anticipating either further downside or a sharp "V-shaped" bounce from oversold levels.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as the market grapples with surging layoff numbers and concerns over the sustainability of massive AI capital expenditures by major tech firms following earnings, with a sharp crypto sell-off further fueling broad market anxiety and prompting community discussion linking it to recent news.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amidst a significant downturn in the cryptocurrency market, particularly Bitcoin, which is heavily impacting the stock as the community actively debates its strong correlation to digital assets and anticipates upcoming earnings.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending after strong Q4 earnings, notably robust growth in Google Cloud and Search driven by AI, yet the market is debating its significantly increased capital expenditure guidance for 2026, with some seeing it as a strategic investment for AI dominance and others as an overextension.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

The community is highly focused on IREN's imminent earnings report, grappling with concerns about Bitcoin's recent decline impacting mining profitability versus the strong tailwinds from massive hyperscaler AI capex and potential new data center deals. Many view the stock's significant pre-earnings volatility and sell-off as market manipulation to acquire shares cheaply.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as Google's substantial AI CAPEX plans reaffirm robust demand for AI infrastructure, yet broader tech sector volatility and ongoing US-China chip export reviews fuel community debate on whether current pullbacks are a buying opportunity or a signal for further downside.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as its Q4 earnings beat and strong Cloud growth are overshadowed by plans for massive AI infrastructure capital expenditures, leading to divided community sentiment on whether the aggressive spending is a strategic long-term play or a cash flow concern in the current volatile tech market.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the stock...

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 38.2% in December

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totaling 2,568,740 shares...

Avalo Therapeutics' (AVTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed a "buy" rating and issued a $25.00 target price on shares of Avalo Therapeutics in a report on Thursday...

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Rating of "Moderate Buy" from Analysts

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eleven brokerages that are presently covering the stock, MarketBeat.com...

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are presently covering the firm, MarketBeat...

Avalo Therapeutics (NASDAQ:AVTX) Upgraded by Mizuho to "Strong-Buy" Rating

Mizuho upgraded Avalo Therapeutics to a "strong-buy" rating in a research report on Thursday...

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten analysts that are covering the company, Marketbeat.com reports. One...

Avalo Therapeutics (NASDAQ:AVTX) Posts Quarterly Earnings Results, Misses Estimates By $0.52 EPS

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($2.19) earnings per share (EPS) for the quarter, missing analysts...

<ul class="summary-bullets"><li>Retail chatter around Avalo rose ahead of an Oppenheimer conference call set to discuss its lead hidradenitis suppurativa drug, AVTX-009, now in a mid-stage trial with topline results expected in 2026.</li><li>Analysts at H.C. Wainwright, Oppenheimer, TD Cowen, and Cantor Fitzgerald maintain bullish views on Avalo, with price targets ranging from $25 to $35 and expectations that AVTX-009 could outperform AbbVie’s rival therapy.</li><li>On Stocktwits, sentiment turned ‘extremely bullish’ as message activity surged; users highlighted fresh opportunities and long-term upside.</li></ul>Shares of Avalo Therapeutics gained 0.4% in premarket trading on Wednesday amid upbeat investor sentiment ahead of an Oppenheimer analyst call focused on its lead drug candidate, AVTX-009, for hidradenitis suppurativa.&nbsp;The stock is currently trading at a nearly 18-month high.&nbsp;<h2 class="st-heading-2">Pipeline And Trial Progress</h2>Earlier this month, Avalo said it had dosed the first patient in the LOTUS study. The randomized, double-blind, placebo-controlled trial is testing two dosing regimens of AVTX-009, with top-line results expected in 2026.The study’s primary endpoint is the proportion of patients achieving HiSCR75, a 75% reduction in abscess and nodule count at week 16, while secondary measures include HiSCR50 and HiSCR90 response rates, improvements in skin pain and lesion severity, and safety outcomes.AVTX-009 targets interleukin-1β, a cytokine involved in the inflammatory cascade driving HS and several other autoimmune diseases. The drug’s mechanism builds on clinical validation seen with other IL-1 inhibitors and aims to deliver higher potency and longer durability.<h2 class="st-heading-2">Analyst Views&nbsp;</h2>Avalo has drawn attention from multiple brokerages since restarting its HS program this year.In September, H.C. Wainwright raised its price target on Avalo Therapeutics to $25 from $15 and reiterated a ‘Buy’ rating, saying AbbVie’s latest hidradenitis suppurativa data validated the IL-1 pathway but capped efficacy at 45%–50% HiSCR75.Earlier that month, Oppenheimer recommended investors be buyers of Avalo shares ahead of lutikizumab’s open-label Phase 2 data, forecasting “strong results” and expecting AVTX-009, with multiple advantages over lutikizumab, to deliver “at least as good as, and potentially better, efficacy” when LOTUS trial results&nbsp;are read out in mid-2026. The firm maintained an ‘Outperform’ rating and a $35 price target.Separately, TD Cowen initiated coverage with a ‘Buy’ rating, citing AVTX-009’s Phase 2 study in hidradenitis suppurativa and highlighting the high unmet need in a heterogeneous patient population, estimating over $1 billion sales potential.&nbsp;Cantor Fitzgerald also began coverage with an ‘Overweight’ rating, describing Avalo as a clinical-stage biotech focused on autoimmune diseases and noting that AVTX-009, an IL-1N2 antibody, is expected to have a mid-2026 readout.<h2 class="st-heading-2">Stocktwits Traders See Long-Term Upside</h2>On Stocktwits, retail sentiment for Avalo was ‘extremely bullish’ amid a 20% surge in 24-hour message volume.One user noted that the setup still offered opportunities and encouraged others to stay tuned.<stembedurl>https://stocktwits.com/topstockalerts/message/632967338</stembedurl>Another user suggested that Avalo looked like a strong buy and could deliver twentyfold returns for investors willing to hold long term.<stembedurl>https://stocktwits.com/WallGoodman/message/632883343</stembedurl><a href="https://stocktwits.com/symbol/AVTX">Avalo’s stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Avalo’s stock has more than doubled so far in 2025. (Photo credit: Getty Images)

Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug

Retail chatter around Avalo rose ahead of an Oppenheimer conference call set to discuss its lead hidradenitis suppurativa drug, AVTX-009, now in a mid-stage trial with topline results expected in 2026.

Equity

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMZN earnings on Thursday?

AVTX
Avalo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AVTX News

AVTXAvalo Therapeutics Inc